Enterprise Value

3.382B

Cash

520.9M

Avg Qtr Burn

-64.23M

Short % of Float

8.04%

Insider Ownership

4.47%

Institutional Own.

79.47%

Qtr Updated

03/31/24


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
Fazirsiran (ARO-AAT) (TAK-999) Details
Severe alpha-1 antitrypsin deficiency, Liver disease

Phase 3

Update

Plozasiran (ARO-APOC3) Details
Familial chylomicronemia syndrome

Phase 3

Update

Plozasiran (ARO-APOC3) Details
Severe hypertriglyceridemia

Phase 3

Initiation

Phase 3

Initiation

Phase 2b

Update

ARO-ANG3 Details
Dyslipidemia

Phase 2

Update

ARO-CFB Details
Complement mediated diseases, Kidney disease, IgA nephropathy

Phase 1/2

Data readout

ARO-DM1 Details
Myotonic Dystrophy Type 1

Phase 1/2

Data readout

ARO-MUC5AC Details
Lung disease, Muco-Obstructive Lung Diseases

Phase 1/2

Data readout

ARO-C3 (RNAi) Details
Renal disease, Paroxysmal nocturnal hemoglobinuria

Phase 1/2

Data readout

ARO-MMP7 Details
Idiopathic pulmonary fibrosis

Phase 1/2

Data readout

ARO-RAGE Details
Muco-Obstructive Lung Diseases, Inflammatory disease, Asthma

Phase 1/2

Update

ARO-DUX4 Details
Facioscapulohumeral muscular dystrophy

Phase 1/2

Initiation

Failed

Discontinued

ARO-HSD Details
Liver disease, Non-alcoholic steatohepatitis

Failed

Discontinued